Hereditary Angioedema Treatment Market to be at Forefront by 2027

Hereditary Angioedema Treatment Market: Introduction

·        Transparency Market Research has published a new report on the hereditary angioedema treatment market for the forecast period of 2019–2027. According to the report, the global hereditary angioedema treatment market was valued at ~US$ 2 Bn in 2018, and is projected to expand at a CAGR of ~9% from 2019 to 2027.

·        Hereditary angioedema is an autosomal disorder, wherein, the level of functional C1 esterase inhibitor protein is low. This leads to increased concentration of bradykinin, which results in fluid leakage from the blood vessels, followed by swelling.

·        Purified concentrate of C1 esterase inhibitors are administered to HAE affected patients for the prophylactic and acute attack treatment of HAE. Several drugs have been approved for the prophylactic and acute attack treatment of hereditary angioedema.

Request a PDF Brochure - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=74333

Increase in Awareness about Hereditary Angioedema and Novel Pipeline Drugs to Drive Market

·        Government organizations and other agencies are creating public awareness through various campaigns regarding the diagnosis, treatment, and care of hereditary angioedema. Moreover, the prevalence of rare diseases across the world is increasing, and most of these are genetic disorders.

·        The U.S. Hereditary Angioedema Association (U.S. HAEA) organized a fundraising event and other campaigns in September 2017 to create awareness about the disorder within the community. Such campaigns boost the growth of the global hereditary angioedema treatment market.

Kallikrein Inhibitors to be Promising Drug Class

·        In terms of drug class, the global hereditary angioedema treatment market has been classified into C1 esterase inhibitors, selective bradykinin B2 receptor antagonists, kallikrein inhibitors, and others.

·        The C1 esterase inhibitors segment dominated the global market in 2018. However, the segment is anticipated to lose market share by the end of 2027, due to expiration of the market exclusivity of certain drugs in major markets, and expected launch of other class of drugs during the forecast period.

Request for Analysis of COVID19 Impact on Hereditary angioedema market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=74333

Subcutaneous Injection Route of Administration Dominates Global Market

·        Based on route of administration, the global hereditary angioedema treatment market has been divided into intravenous, subcutaneous injection, and oral.

·        The subcutaneous injection segment dominated the global market in 2018, and the trend is likely to continue during the forecast period. Patient convenience and new product launches such as Haegarda and Takhzyro in 2017 and 2018, respectively, are the major factors driving the segment in the global hereditary angioedema treatment market.

Retail Pharmacies Prominent Distribution Channel

·        In terms of distribution channel, the global hereditary angioedema treatment market has been categorized into hospital pharmacies, retail pharmacies, and others.

·        The retail pharmacies segment is projected to dominate the global hereditary angioedema treatment market during the forecast period, owing to increase in the number of retail pharmacies, easy accessibility, and additional services provided by specialty pharmacies.

Request a Sample of Hereditary angioedema market: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=74333

North America to Dominate Global Hereditary Angioedema Treatment Market

·        The global hereditary angioedema treatment market has been segmented into three major regions: North America, Europe, and Rest of the World.

·        North America accounted for a major share of the global hereditary angioedema treatment market in 2018, and is projected to dominate the market during the forecast period.

·        High prevalence of hereditary angioedema, comparatively better reported ratio for diseases, high healthcare expenditure, and availability of specialty HAE products are the major factors boosting the growth of the hereditary angioedema treatment market North America.

Enquiry before Buying Hereditary angioedema market Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=74333

Global Hereditary Angioedema Treatment Market: Competitive Landscape

·        Shire plc (Takeda Pharmaceutical Company Limited), CSL Limited, and Pharming Group NV are leading players in the global hereditary angioedema treatment market.

·        The global hereditary angioedema treatment market is projected to be driven by novel therapies and pipeline products during the forecast period. These pipeline products are in various clinical trial phases, and are expected to be launched in the next few years.